The first treatment decision in advanced non–small cell lung cancer increasingly depends on information that is not visible on the staging scan or routine histology report.
Two patients with metastatic lung adenocarcinoma may appear clinically similar but require fundamentally different first-line strategies because one tumor carries an actionable driver alteration and the other does not. A third patient may have high PD-L1 expression, but that result alone cannot establish the correct treatment pathway until clinically relevant molecular alterations have been excluded.
For this reason, molecular testing turnaround is no longer only a laboratory performance issue. It is a treatment-quality issue.
The challenge is particularly visible in community oncology, where tissue may travel between hospitals, pathology departments, reference laboratories, pulmonologists, radiologists, and oncology practices before a complete report reaches the treating clinician.
How can community teams obtain comprehensive results before first-line therapy without creating an unsafe delay for a patient with symptomatic or rapidly progressing disease?
This question will be addressed at the OncoDaily Community Oncology Global Congress 2026, where international experts and frontline oncology professionals will discuss practical strategies for delivering timely, biomarker-directed care outside major academic centers. The virtual congress will take place from August 28 to 30, 2026.
The First-Line Decision Starts Before the Prescription
Modern advanced NSCLC treatment is divided broadly into tumors with an actionable oncogenic driver and those without one.
When a therapeutically relevant driver is detected, the appropriate first-line strategy may involve a targeted treatment designed specifically for that molecular alteration. When testing does not identify a driver, histology, PD-L1 expression, clinical condition, comorbidities, and patient preferences guide the choice among immunotherapy-based regimens.
The 2026 ASCO living guidelines emphasize comprehensive testing before frontline therapy. The guidance supports a validated tissue- and/or blood-based broad multigene panel, together with appropriate immunohistochemistry testing, including PD-L1, HER2, and MET. The guideline discussion also emphasizes that PD-L1 testing alone is not sufficient to define the treatment pathway (Puri et al., 2026; Reuss et al., 2026).
This makes the timing of testing inseparable from the timing of treatment. A result that arrives after the first infusion may still be clinically useful, but it has already missed the most important decision point.
Why Is a High PD-L1 Result Not Enough?
A high PD-L1 tumor proportion score can support the use of immunotherapy in advanced NSCLC without an actionable driver. However, it cannot substitute for comprehensive molecular profiling.
Some tumors with oncogenic drivers can also express PD-L1. If treatment is selected from the PD-L1 result alone, a patient who could have received molecularly matched therapy may instead begin an immunotherapy-based regimen.
The absence of an actionable alteration therefore needs to be demonstrated with adequate testing rather than assumed from age, smoking history, ethnicity, tumor appearance, or PD-L1 expression.
This is one of the most important practical changes in lung oncology: molecular testing is no longer a test ordered only when the clinician strongly suspects a driver. It is part of the initial treatment assessment for advanced NSCLC (Puri et al., 2026; Reuss et al., 2026).
What Does “Turnaround Time” Actually Measure?
Turnaround time is often described as the interval between a laboratory receiving a specimen and issuing a report. That number is important, but it captures only one part of the pathway.
The full clinical interval begins much earlier. It may include the time from biopsy to pathological diagnosis, molecular test ordering, specimen retrieval, pathology review, tissue preparation, shipment to an external laboratory, sequencing, interpretation, report delivery, and oncology review.
A laboratory can complete sequencing quickly while the patient still waits several weeks because the test was not ordered immediately.
A 2026 study by Fox and colleagues analyzed 271,574 solid-tumor samples submitted from 5,497 clinical sites between 2018 and 2024. Median overall turnaround time from specimen collection to comprehensive genomic profiling report decreased from 43 days in 2018 to 32 days in 2024. However, the greatest contributor to prolonged turnaround was the delay between biopsy and test ordering, which varied substantially among clinical sites (Fox et al., 2026).
Read About Article on OncoDaily Lung
The finding shifts attention away from the sequencing platform alone. Faster laboratory processing cannot fully solve a pathway in which the sample waits days or weeks before testing is requested.
What Is the Benchmark for Molecular Results?
The CAP–IASLC–AMP molecular testing guideline established a benchmark of approximately 10 working days from receipt of the specimen in the molecular laboratory to reporting of results. When testing is performed externally, specimens should be transferred to the testing laboratory promptly, with a suggested target of no more than three working days (Lindeman et al., 2018).
The benchmark is useful, but community practices also need to measure the complete patient-facing pathway.
A laboratory turnaround time of eight days may appear successful. If the test was ordered 14 days after biopsy and required another week for tissue retrieval, the result may still arrive too late for the first-line consultation.
Quality improvement therefore needs at least two measures: the laboratory interval and the total interval from tissue acquisition to an actionable report being available to the treating team.
Reflex Testing Can Start the Clock Earlier
In an oncologist-initiated model, molecular testing may not begin until after pathology is finalized, staging is completed, the patient has been referred, and the first oncology visit has occurred.
Reflex testing changes this sequence.
Under a predefined protocol, the pathology team initiates appropriate molecular testing once the diagnosis, histology, stage, and specimen criteria are met. The test does not wait for a separate oncology order.
This approach can remove several avoidable handoffs from the pathway. It may also increase testing rates by ensuring that eligible samples enter the molecular workflow consistently rather than depending on individual ordering patterns.
The American Cancer Society National Lung Cancer Roundtable identified reflex testing, early multidisciplinary communication, standardized tissue handling, electronic ordering, predefined testing algorithms, and active tracking of insufficient specimens as key strategies for reducing NSCLC biomarker turnaround. The group also warned that sequential single-gene testing can consume limited tissue and prolong the time required to obtain a complete molecular profile (Roy-Chowdhuri et al., 2024).
Reflex testing is not simply ordering faster. It requires agreement among pathology, pulmonology, radiology, surgery, oncology, and laboratory teams about which patients qualify, which assay will be used, who receives the result, and what happens when tissue is inadequate.
Why Broad NGS Is Favored Over Sequential Testing
Sequential testing examines one gene or alteration at a time. It can provide a rapid answer when the suspected target is clear, but it becomes inefficient as the number and technical diversity of clinically relevant biomarkers expand.
Some alterations are point mutations. Others are insertions, deletions, splice changes, amplifications, or gene fusions. A testing strategy designed around a small number of individual assays may miss alterations that require different methods.
Sequential testing can also exhaust small biopsy samples before the full panel is complete. This creates a risk that the first tests are negative and insufficient tissue remains for the later ones.
Broad next-generation sequencing evaluates multiple genomic alterations simultaneously and can preserve tissue by reducing repeated assay preparation. RNA-based sequencing can be especially useful for detecting gene fusions that may not be reliably identified by DNA-only approaches (Puri et al., 2026).
The practical objective is not to order the largest possible panel without clinical purpose. It is to obtain a sufficiently comprehensive result, using a validated platform, before the first treatment decision is finalized.
Tissue and Plasma Are Complementary, Not Competing
Tissue remains central to the diagnosis of NSCLC. It establishes histology, permits immunohistochemistry, confirms tumor content, and supports molecular analysis.
However, tissue testing can be delayed by biopsy scheduling, specimen retrieval, decalcification, insufficient tumor material, or the need to send slides and blocks to a reference laboratory.
Plasma circulating tumor DNA testing offers a complementary route. Blood can often be collected at the first oncology or diagnostic visit, and processing does not depend on locating or shipping a tissue block.
In the ACCELERATE clinical trial, median turnaround from sample collection to genotyping results was seven days for plasma testing and 23 days for tissue NGS. The study evaluated ctDNA testing before a confirmed tissue diagnosis while maintaining tissue sampling as an essential part of the diagnostic pathway.
A prospective randomized study in treatment-naïve advanced NSCLC also found that performing liquid NGS at the initial clinical visit shortened median time to treatment from 28 days to 20 days and identified additional patients eligible for targeted therapy (Yang et al., 2023).
The strongest community workflow may therefore be a parallel approach: tissue is obtained for diagnosis, histology, PD-L1, and comprehensive profiling, while plasma testing begins early when faster molecular information could affect treatment.
A positive, validated plasma result can be clinically informative. A negative plasma result is different. Some tumors release little circulating DNA, so an uninformative blood test does not exclude an actionable alteration. Tissue testing remains necessary when plasma does not identify a driver and adequate tissue can be obtained.
What Happens When the Tissue Is Insufficient?
Insufficient tissue is not only a laboratory problem. It often reflects decisions made before the specimen enters the molecular laboratory.
The biopsy method, lesion selected, needle size, number of passes, specimen processing, use of rapid on-site evaluation, tumor cellularity, and distribution of material between diagnostic stains and molecular testing can all influence whether comprehensive analysis is possible.
A successful community pathway begins before biopsy. The proceduralist needs to know that the sample must support diagnosis, immunohistochemistry, and molecular profiling. The pathologist needs to conserve tissue and avoid unnecessary staining. The oncology team needs rapid notification when the specimen is inadequate so that plasma testing or repeat biopsy can be considered without losing another treatment cycle.
A “quantity not sufficient” result should trigger a defined rescue pathway rather than return to an unstructured series of phone calls and new referrals (Roy-Chowdhuri et al., 2024).
Can Every Patient Safely Wait for Complete Results?
Not every patient with advanced NSCLC arrives clinically stable.
Some patients have rapidly worsening respiratory symptoms, extensive organ involvement, severe pain, bleeding, neurological compromise, or declining performance status. In these cases, the clinical team may be forced to begin treatment before every molecular result is available.
The important distinction is between a necessary clinical decision and an avoidable operational delay.
A patient should not wait because a test order sat unsigned, a tissue block remained unrequested, or no one tracked the external laboratory report. At the same time, molecular testing should not become a rigid rule that delays urgent stabilization in a patient with immediately threatening disease.
When urgent treatment is required, the team needs a documented strategy that considers histology, available preliminary biomarkers, likely treatment alternatives, expected result timing, and whether plasma testing can accelerate the decision.
This is where multidisciplinary communication matters most. The question is not simply, “Should we wait?” It is, “How much clinical risk is created by waiting, and how much treatment risk is created by acting without the complete result?”
Building a Community NSCLC Testing Pathway
An effective pathway begins when advanced lung cancer is suspected rather than when the patient reaches the medical oncologist.
The biopsy request should indicate the need for molecular profiling. Tissue conservation should be planned before extensive immunohistochemistry is performed. Reflex testing criteria should be agreed upon in advance. Plasma testing should be available when tissue is limited or when a parallel strategy can shorten the diagnostic interval.
The practice also needs ownership. One person or team must be responsible for tracking the sample from biopsy through result review. Electronic alerts can identify tests that were ordered but not received, samples delayed in shipment, or reports returned after treatment has already begun.
Turnaround should be audited regularly. Practices need to know the median time from biopsy to test order, order to specimen dispatch, laboratory receipt to report, and report to treatment decision.
The 2026 Fox analysis found major differences between clinical sites, showing that local workflow, not only assay technology, can determine how quickly genomic information reaches the patient.
Why This Matters for Global Community Oncology
The barriers are not identical across healthcare systems.
Some practices have access to in-house NGS, integrated pathology, molecular tumor boards, and same-day plasma collection. Others depend on distant reference laboratories, international specimen shipping, limited insurance coverage, or out-of-pocket testing.
In lower-resource settings, the choice may not be between two comprehensive platforms. It may be between a limited panel and no testing at all.
A practical global discussion must therefore address both the ideal pathway and adaptable alternatives. This includes determining the minimum clinically useful panel, prioritizing assays when resources are constrained, building regional laboratory networks, improving specimen transport, expanding virtual molecular tumor boards, and ensuring that identifying a target is followed by access to the corresponding therapy.
Testing without treatment access is incomplete precision medicine. Treatment without appropriate testing is imprecise care.
Join the Discussion at the Community Oncology Global Congress
Molecular Testing Turnaround Before First-Line Therapy in Advanced NSCLC will be among the practical care-delivery challenges examined at the OncoDaily Community Oncology Global Congress 2026.
The discussion will move beyond whether broad molecular testing is recommended. It will focus on how community teams can make the recommendation operational.
Experts and participants will examine when testing should be initiated, whether reflex pathways can shorten delays, how tissue and liquid biopsy can be coordinated, what turnaround metrics practices should measure, and how clinicians can manage patients who need treatment before the full report is available.
The congress will bring together community oncologists, multidisciplinary cancer professionals, healthcare leaders, researchers, advocates, and policymakers from different regions to discuss solutions that can be adapted across diverse healthcare environments. Registration is open for the virtual event taking place August 28–30, 2026.
The Bottom Line
In advanced NSCLC, the first-line treatment decision should be based on more than histology and PD-L1 expression.
Comprehensive molecular profiling can identify patients who require a targeted treatment pathway and confirm which patients should proceed to an immunotherapy-based strategy.
The laboratory benchmark of approximately 10 working days remains important, but the greatest delays may occur before the specimen reaches the laboratory. Late ordering, tissue retrieval, fragmented communication, sequential testing, and inadequate samples can turn a technically fast assay into a clinically late result.
Reflex testing, parallel tissue and plasma profiling, tissue-conservation protocols, defined rescue pathways, and active result tracking can bring molecular information closer to the first-line decision.
The central goal is not testing for its own sake. It is ensuring that the right result reaches the right clinician before the patient receives the wrong first treatment.
References
- Puri S, Leighl NB, Ismaila N, et al. Therapy for stage IV non–small cell lung cancer with driver alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7):e15–e55. doi:10.1200/JCO-25-02822.
- Reuss JE, Bazhenova L, Ismaila N, et al. Therapy for stage IV non–small cell lung cancer without driver alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7):e56–e88. doi:10.1200/JCO-25-02825.
- Fox AH, Keller-Evans RB, Huang RSP, Silvestri GA. Turnaround time of comprehensive genomic profiling in lung cancer and other solid tumors. JCO Oncology Practice. Published online June 18, 2026. doi:10.1200/OP-25-01191.
- Roy-Chowdhuri S, Mani H, Fox AH, et al. The American Cancer Society National Lung Cancer Roundtable strategic plan: methods for improving turnaround time of comprehensive biomarker testing in non–small cell lung cancer. Cancer. 2024. doi:10.1002/cncr.34926.
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2018;13(3):323–358.
- Yang CY, et al. Upfront liquid next-generation sequencing in treatment-naïve advanced non–small cell lung cancer: a prospective randomized study. European Journal of Cancer. 2023.